|By PR Newswire||
|February 26, 2014 05:00 AM EST||
KOLKATA, India, February 26, 2014 /PRNewswire/ --
- The careHPV™ Test is the first HPV diagnostic designed for regions with limited healthcare infrastructure, complementing QIAGEN's market-leading digene HC2 HPV Test
- Commercial launch of careHPV Test in India enables high-quality screening for prevention of cervical cancer among women in low-resource areas
- The careHPV Test plays an important role in QIAGEN's Corporate Social Responsibility effort around the world, especially in low-resource areas
QIAGEN N.V. today announced the commercial launch in India of its careHPV™ Test, the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with limited healthcare infrastructure, such as areas lacking electricity, water or laboratories. HPV is the primary cause of cervical cancer in women, so screening for the viral infection is a powerful strategy for prevention and early treatment of the deadly cancer. The careHPV Test was launched commercially in China in 2013 and has been used in several other countries, including as part of QIAGEN's corporate social responsibility effort, QIAGENcares.
The careHPV Test for low-resource settings is highly complementary with QIAGEN's digene HC2 HPV Test, the world's most validated and sensitive diagnostic test for detection of high-risk HPV. The digene HC2 HPV Test is recognized as the "gold standard" in HPV screening and is widely used in developed countries and in large cities in emerging markets.
About 72,000 women in India die of cervical cancer each year, more than one-fourth of the world's 270,000 annual deaths. In India, cervical cancer accounts for about 20% of all cancer-related deaths in women and is the number one cause of death in middle-aged Indian women.
"The launch of careHPV in India will help in efforts to reduce the high burden of cervical cancer for women in India," said Dr. Victor Shi, President of QIAGEN Asia Pacific. "With the digene HC2 HPV Test serving areas that have modern healthcare infrastructure and the careHPV Test serving low-resource areas, QIAGEN is expanding our role as the global leader in preventive screening for cervical cancer and continuing to contribute to women's health around the world."
Dr. Partha Basu, Head of the Department of Gynecological Oncology and Officer In Charge, Division of Preventive Oncology, Chittaranjan National Cancer Institute, noted the importance of the two-tiered approach to screening: "Based on the findings of the screening project that we have been doing for four years in Kolkata and surrounding areas, there is a need for a cost-effective and easy-to-use test which can best meet the requirements of low-resource settings. Availability of the careHPV Test is an important step forward for the prevention of cervical cancer in India."
QIAGEN's robust, portable and easy-to-use careHPV Test combines the power of advanced molecular technologies with innovative design and features. For example, the system has color-coded, easy-to-understand menus and self-contained reagents. The test tolerates temperature variations that occur in rural clinics lacking refrigeration for sample storage due to limited electricity or water, and can provide results much faster. The careHPV Test was developed with support from PATH, an international nonprofit organization, and is manufactured by QIAGEN in Shenzhen, China.
The careHPV Test already plays an important role in QIAGENcares, QIAGEN's collaborations with NGOs and governments in which it helps expand access to high-quality cervical cancer screening in resource-poor regions. For example, tests for cervical cancer have been conducted on women in El Salvador using the careHPV Tests since 2012. The test will also be used in other countries, including Vanuatu.
Also as part of QIAGENcares, QIAGEN and the Chittaranjan National Cancer Institute (CNCI) started a five-year-program in 2010 to provide cervical cancer screening with the digene HC2 HPV Test to 50,000 women in rural West Bengal. Screening is facilitated through mobile field clinics. This project has screened more than 36,000 women to date and has detected 216 cases of High Grade Squamous Intra-epithelial Lesions (HSIL) and 52 cases of cervical cancers. Most of the cervical cancers were at early treatable stages, and more than 90% of these patients have been treated at CNCI. In addition, many doctors and community-based healthcare workers have been trained in HPV screening. This project is the first HPV based screening project in India, demonstrating program aspects and successful implementation with clear deliverables.
Cervical cancer is the second most common cancer among women worldwide, and research has shown that 80% of new cases and deaths occur in developing countries, where awareness of the disease and access to preventive tests and medical treatment is low. In many low-resource areas, cervical cancer has eclipsed breast cancer as the primary cancer killer of women.
To learn more about QIAGENcares please visit:
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2013, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at http://www.QIAGEN.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Dr. Thomas Theuringer
Director Public Relations
Communications Manager APAC
Email: [email protected]
Vice President Corporate Communications and Investor Relations
Email: [email protected]
Large scale deployments present unique planning challenges, system commissioning hurdles between IT and OT and demand careful system hand-off orchestration. In his session at @ThingsExpo, Jeff Smith, Senior Director and a founding member of Incenergy, will discuss some of the key tactics to ensure delivery success based on his experience of the last two years deploying Industrial IoT systems across four continents.
Jul. 27, 2016 04:00 AM EDT Reads: 1,547
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Jul. 27, 2016 03:45 AM EDT Reads: 1,155
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
Jul. 27, 2016 03:30 AM EDT Reads: 944
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
Jul. 27, 2016 03:15 AM EDT Reads: 1,749
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Jul. 27, 2016 02:45 AM EDT Reads: 2,244
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 27, 2016 02:45 AM EDT Reads: 1,516
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
Jul. 27, 2016 02:15 AM EDT Reads: 1,425
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Jul. 27, 2016 02:15 AM EDT Reads: 2,582
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 27, 2016 02:00 AM EDT Reads: 1,717
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
Jul. 27, 2016 12:00 AM EDT Reads: 2,001
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
Jul. 27, 2016 12:00 AM EDT Reads: 1,941
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effi...
Jul. 26, 2016 11:00 PM EDT Reads: 2,006
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo Silicon Valley Call for Papers is now open.
Jul. 26, 2016 11:00 PM EDT Reads: 2,582
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Jul. 26, 2016 10:45 PM EDT Reads: 1,099
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 26, 2016 10:45 PM EDT Reads: 1,364